ReviewJournal of Parkinson's disease2020
Does Developmental Variability in the Number of Midbrain Dopamine Neurons Affect Individual Risk for Sporadic Parkinson's Disease?
Review in Journal of Parkinson's disease, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Impact of aging on animal models of Parkinson's disease.Frontiers in aging neuroscience · 2022Pooled it
- The dopaminergic system in neurodevelopment: preclinical models of neurodevelopmental disorders and susceptibility to neurodegeneration.Frontiers in cellular neuroscience · 2026Review
- Research progress on the association of maternal high-fat diet with offspring neurodevelopment and susceptibility to Parkinson's disease.Frontiers in nutrition · 2026Review
- Helicobacter pylori infection and α-synuclein pathology drive parallel neurodegenerative pathways in the substantia nigra.Journal of neuroinflammation · 2025Article
- Implications for the role of natural products in Parkinson disease therapy.Archives of medical science : AMS · 2025Article
- Human α-synuclein overexpression upregulates SKOR1 in a rat model of simulated nigrostriatal ageing.Aging cell · 2024Article
- Article
- The Parkinson's disease variant rs356182 regulates neuronal differentiation independently from alpha-synuclein.Human molecular genetics · 2023Article
- Genomic, transcriptomic, and metabolomic profiles of hiPSC-derived dopamine neurons from clinically discordant brothers with identical PRKN deletions.NPJ Parkinson's disease · 2022Article
- Preventive Vitamin A Supplementation Improves Striatal Function in 6-Hydroxydopamine Hemiparkinsonian Rats.Frontiers in nutrition · 2022Article
- Genetic Elements at the Alpha-Synuclein Locus.Frontiers in neuroscience · 2022Review
- Developmental pathways linked to the vulnerability of adult midbrain dopaminergic neurons to neurodegeneration.Frontiers in molecular neuroscience · 2022Review
- Review
- The enigma and implications of brain hemispheric asymmetry in neurodegenerative diseases.Brain communications · 2021Review
- Precision medicine in Parkinson's disease patients with LRRK2 and GBA risk variants - Let's get even more personal.Translational neurodegeneration · 2020Review
- Neurotrophic factors for disease-modifying treatments of Parkinson's disease: gaps between basic science and clinical studies.Pharmacological reports : PR · 2020Review
- The Role of Alpha-Synuclein and Other Parkinson's Genes in Neurodevelopmental and Neurodegenerative Disorders.International journal of molecular sciences · 2020Review
- Post-GWAS knowledge gap: the how, where, and when.NPJ Parkinson's disease · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Parkinson's disease (PD) is a slowly progressing neurodegenerative disorder that is coupled to both widespread protein aggregation and to loss of substantia nigra dopamine (DA) neurons, resulting in a wide variety of motor and non-motor signs and symptoms. Recent findings suggest that the PD process is triggered several years before there is sufficient degeneration of DA neurons to cause onset of overt motor symptoms. According to this concept, the number of DA neurons present in the substantia nigra at birth could influence the time from the molecular triggering event until the clinical diagnosis with lower number of neurons at birth increasing the risk to develop the disease. Conversely, the risk for diagnosis would be reduced if the number of DA neurons is high at birth. In this commentary, we discuss the genetic and epigenetic factors that might influence the number of nigral DA neurons that each individual is born with and how these may be linked to PD risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.